Journal article
Rociletinib in EGFR-mutated non-small-cell lung cancer
LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, V Papadimitrakopoulou, BJ Solomon, GR Oxnard, R Dziadziuszko, DL Aisner, RC Doebele, C Galasso, EB Garon, RS Heist, J Logan, JW Neal, MA Mendenhall, S Nichols, Z Piotrowska Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2015
Abstract
BACKGROUND: Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases. Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M. METHODS: In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor. In the expansion (phase 2) part of the study, patients with T790Mpositive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Supported by Clovis Oncology.